Tumor metabolism of lactate: The influence and therapeutic potential for MCT and CD147 regulation

Future Oncology

Volumn 6, Issue 1, 2010, Pages 127-148

  Kennedy, Kelly M ^a   Dewhirst, Mark W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer; CD147; Lactate; MCT1; MCT1 inhibitors; MCT4; Tumor metabolism

Indexed keywords

AR C 117977; CD147 ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOSUPPRESSIVE AGENT; LACTIC ACID; MONOCARBOXYLATE TRANSPORTER; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 4; UNCLASSIFIED DRUG;

ACIDOSIS; AMINO ACID METABOLISM; BRAIN; BRAIN CANCER; BREAST CANCER; CARCINOGENESIS; COLORECTAL CANCER; ENZYME GLYCOSYLATION; ESOPHAGUS CANCER; GALLBLADDER CARCINOMA; HEAD AND NECK CANCER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LACTATE METABOLISM; LACTATE UTILIZATION; LACTOSIS; LIVER CANCER; LUNG CANCER; MELANOMA; MICROENVIRONMENT; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; TRANSCRIPTION REGULATION; TUMOR; UTERINE CERVIX CANCER; WOUND HEALING;

ANIMALS; ANTIGENS, CD147; HUMANS; LACTIC ACID; MONOCARBOXYLIC ACID TRANSPORTERS; NEOPLASMS;

EID: 75149178349     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.145     Document Type: Review

References (178)

1. Warburg O: On the origin of cancer cells. Science 123(3191), 309-314 (1956).
2. Warburg O: On respiratory impairment in cancer cells. Science 124(3215), 269-270 (1956).
3. Warburg OH, Dickens F; Kaiser-Wilhelm-Institut Fuir Biologie: The metabolism of tumours : investigations from the Kaiser Wilhelm Institute for Biology, Berlin-Dahlem. Constable, London, UK (1930).
4. Warburg OH; Kaiser-Wilhelm-Institut Fuì̂R Biologie: Ãoeber den stoffwechsel der tumoren: arbeiten aus dem kaiser wilheim-institut fã1/2r biologie, berlin-dahlem. Julius Springer, Berlin, Germany (1926).
5. Waterhouse C: Lactate metabolism in patients with cancer. Cancer 33(1), 66-71 (1974).
6. Holroyde CP, Axelrod RS, Skutches CL, Haff AC, Paul P, Reichard GA: Lactate metabolism in patients with metastatic colorectal cancer. Cancer Res. 39(12), 4900-4904 (1979).
7. Paschen W: Regional quantitative determination of lactate in brain sections. A bioluminescent approach. J. Cereb. Blood Flow Metab. 5(4), 609-612 (1985).
8. Paschen W, Mies G, Kloiber O, Hossmann KA: Regional quantitative determination of brain glucose in tissue sections: a bioluminescent approach. J. Cereb. Blood Flow Metab. 5(3), 465-468 (1985).
9. Paschen W, Djuricic B, Mies G, Schmidt-Kastner R, Linn F: Lactate and pH in the brain: association and dissociation in different pathophysiological states. J. Neurochem. 48(1), 154-159 (1987).
10. Mueller-Klieser W, Kroeger M, Walenta S, Rofstad EK: Comparative imaging of structure and metabolites in tumours. Int. J. Radiat. Biol. 60(1-2), 147-159 (1991).
11. Tamulevicius P, Streffer C: Metabolic imaging in tumours by means of bioluminescence. Br. J. Cancer 72(5), 1102-1112 (1995).
12. Schwickert G, Walenta S, Sundfor K, Rofstad EK, Mueller-Klieser W: Correlation of high lactate levels in human cervical cancer with incidence of metastasis. Cancer Res. 55(21), 4757-4759 (1995).
13. Walenta S, Salameh A, Lyng H et al.: Correlation of high lactate levels in head and neck tumors with incidence of metastasis. Am. J. Pathol. 150(2), 409-415 (1997).
14. Walenta S, Chau TV, Schroeder T et al.: Metabolic classification of human rectal adenocarcinomas: a novel guideline for clinical oncologists? J. Cancer Res. Clin. Oncol. 129(6), 321-326 (2003).
15. Walenta S, Wetterling M, Lehrke M et al.: High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res. 60(4), 916-921 (2000).
16. Brizel DM, Schroeder T, Scher RL et al.: Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 51(2), 349-353 (2001).
17. Fulham MJ, Bizzi A, Dietz MJ et al.: Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology 185(3), 675-686 (1992).
18. Hossmann KA, Mies G, Paschen W, Szabo L, Dolan E, Wechsler W: Regional metabolism of experimental brain tumors. Acta Neuropathol. 69(1-2), 139-147 (1986).
19. Yokota H, Guo J, Matoba M, Higashi K, Tonami H, Nagao Y: Lactate, choline, and creatine levels measured by vitro 1H-MRS as prognostic parameters in patients with non-small-cell lung cancer. J. Magn. Reson. Imaging 25(5), 992-999 (2007).
20. Gordan JD, Thompson CB, Simon MC: HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 12(2), 108-113 (2007).
21. Jones RG, Thompson CB: Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 23(5), 537-548 (2009).
22. Dewhirst MW, Cao Y, Moeller B: Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat. Rev. Cancer 8(6), 425-437 (2008).
23. Cardenas-Navia LI, Braun R, Lewis K, Dewhirst M: Comparison of fluctuations of oxygen tension in FSA, 9L, and R3230AC tumors in rats. Adv. Exp. Med. Biol. 510, 7-12 (2003).
24. Cardenas-Navia LI, Mace D, Richardson RA, Wilson DF, Shan S, Dewhirst MW: The pervasive presence of fluctuating oxygenation in tumors. Cancer Res. 68(14), 5812-5819 (2008).
25. Lee JW, Bae SH, Jeong JW, Kim SH, Kim KW: Hypoxia-inducible factor (HIF-1) α: Its protein stability and biological functions. Exp. Mol. Med. 36(1), 1-12 (2004).
26. Cardenas-Navia LI, Richardson RA, Dewhirst MW: Targeting the molecular effects of a hypoxic tumor microenvironment. Front. Biosci. 12, 4061-4078 (2007).
27. Vaupel P: Tumor microenvironmental physiology and its implications for radiation oncology. Semin. Radiat. Oncol. 14(3), 198-206 (2004).
28. Schroeder T, Yuan H, Viglianti BL et al.: Spatial heterogeneity and oxygen dependence of glucose consumption in R3230AC and fibrosarcomas of the Fischer 344 rat. Cancer Res. 65(12), 5163-5171 (2005).
29. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100(1), 57-70 (2000).
30. Bergeron R, Russell RR, 3rd, Young LH et al.: Effect of AMPK activation on muscle glucose metabolism in conscious rats. Am. J. Physiol. 276(5 Pt 1), E938-E944 (1999).
31. rd Edition). Brooks Cole, CA, USA, 1216 (2004).
32. Halestrap AP, Meredith D: The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch. 447(5), 619-628 (2004). ■ A thorough review on monocarboxylate transporters of the SLC16A family.
33. rd Edition). Karger Publishers, Basel, Switzerland (2003).
34. Morris ME, Felmlee MA: Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse γ-hydroxybutyric acid. AAPS J. 10(2), 311-321 (2008).
35. Bhattacharya I, Boje KM: Potential γ-hydroxybutyric acid (GHB) drug interactions through blood-brain barrier transport inhibition: a pharmacokinetic simulation-based evaluation. J. Pharmacokinet. Pharmacodyn. 33(5), 657-681 (2006).
36. Pinheiro C, Longatto-Filho A, Scapulatempo C et al.: Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch. 452(2), 139-146 (2008).
37. Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E: Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res. 66(2), 632-637 (2006).
38. Lin RY, Vera JC, Chaganti RS, Golde DW: Human monocarboxylate transporter 2 (MCT2) is a high affinity pyruvate transporter. J. Biol. Chem. 273(44), 28959-28965 (1998).
39. Schneiderhan W, Scheler M, Holzmann KH et al.: CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models. Gut 58(10), 1391-1398 (2009).
40. Gallagher SM, Castorino JJ, Wang D, Philp NJ: Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res. 67(9), 4182-4189 (2007).
41. Chan MM, Lu X, Merchant FM, Iglehart JD, Miron PL: Gene expression profiling of NMU-induced rat mammary tumors: cross species comparison with human breast cancer. Carcinogenesis 26(8), 1343-1353 (2005).
42. Dai Z, Lakshmanan RR, Zhu WG et al.: Global methylation profiling of lung cancer identifies novel methylated genes. Neoplasia 3(4), 314-323 (2001).
43. Daly K, Cuff MA, Fung F, Shirazi-Beechey SP: The importance of colonic butyrate transport to the regulation of genes associated with colonic tissue homoeostasis. Biochem. Soc. Trans. 33(Pt 4), 733-735 (2005).
44. Pinheiro C, Longatto-Filho A, Ferreira L et al.: Increasing expression of monocarboxylate transporters 1 and 4 along progression to invasive cervical carcinoma. Int. J. Gynecol. Pathol. 27(4), 568-574 (2008).
45. +)-coupled transport of lactate. J. Biol. Chem. 279(43), 44522-44532 (2004).
46. +)-coupled transporter for short-chain fatty acids. J. Biol. Chem. 279(14), 13293-13296 (2004).
47. Srinivas SR, Gopal E, Zhuang L et al.: Cloning and functional identification of SLC5A12 as a sodium-coupled low-affinity transporter for monocarboxylates (smct2). Biochem. J. 392(Pt 3), 655-664 (2005).
48. Ganapathy V, Thangaraju M, Gopal E et al.: Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J. 10(1), 193-199 (2008). ■ A review on sodium-coupled monocarboxylate transporters (SMCTs) and their emerging and potential role in normal tissue and cancer.
49. Cori C: Mammalian carbohydrate metabolism. Physiol. Rev. 11(2), 143-275 (1931).
50. Brooks GA: Intra- and extra-cellular lactate shuttles. Med. Sci. Sports Exerc. 32(4), 790-799 (2000).
51. Gladden LB: Lactate metabolism: a new paradigm for the third millennium. J. Physiol. 558(Pt 1), 5-30 (2004). ■ Provides extensive information on lactate metabolism in many systems.
52. Hashimoto T, Hussien R, Cho HS, Kaufer D, Brooks GA: Evidence for the mitochondrial lactate oxidation complex in rat neurons: demonstration of an essential component of brain lactate shuttles. PLoS ONE 3(8), E2915 (2008).
53. Hashimoto T, Hussien R, Oommen S, Gohil K, Brooks GA: Lactate sensitive transcription factor network in l6 cells: Activation of MCT1 and mitochondrial biogenesis. FASEB J. 21(10), 2602-2612 (2007).
54. Gladden LB: Lactic acid: new roles in a new millennium. Proc. Natl Acad. Sci. USA 98(2), 395-397 (2001).
55. Pellerin L, Pellegri G, Bittar PG et al.: Evidence supporting the existence of an activity-dependent astrocyte-neuron lactate shuttle. Dev. Neurosci. 20(4-5), 291-299 (1998).
56. Pellerin L, Pellegri G, Martin JL, Magistretti PJ: Expression of monocarboxylate transporter mRNAs in mouse brain: support for a distinct role of lactate as an energy substrate for the neonatal vs adult brain. Proc. Natl Acad. Sci. USA 95(7), 3990-3995 (1998).
57. Bouzier-Sore AK, Voisin P, Canioni P, Magistretti PJ, Pellerin L: Lactate is a preferential oxidative energy substrate over glucose for neurons in culture. J. Cereb. Blood Flow Metab. 23(11), 1298-1306 (2003).
58. Pellerin L: Lactate as a pivotal element in neuron-glia metabolic cooperation. Neurochem. Int. 43(4-5), 331-338 (2003).
59. Zwingmann C, Richter-Landsberg C, Brand A, Leibfritz D: NMR spectroscopic study on the metabolic fate of [3-(13)c]alanine in astrocytes, neurons, and cocultures: implications for glia-neuron interactions in neurotransmitter metabolism. Glia 32(3), 286-303 (2000).
60. Waagepetersen HS, Sonnewald U, Larsson OM, Schousboe A: A possible role of alanine for ammonia transfer between astrocytes and glutamatergic neurons. J. Neurochem. 75(2), 471-479 (2000).
61. McClelland GB, Khanna S, Gonzalez GF, Butz CE, Brooks GA: Peroxisomal membrane monocarboxylate transporters: evidence for a redox shuttle system? Biochem. Biophys. Res. Commun. 304(1), 130-135 (2003).
62. Storey BT, Kayne FJ: Energy metabolism of spermatozoa. VI. Direct intramitochondrial lactate oxidation by rabbit sperm mitochondria. Biol. Reprod. 16(4), 549-556 (1977).
63. Gaesser GA, Brooks GA: Metabolic bases of excess post-exercise oxygen consumption: a review. Med. Sci. Sports Exerc. 16(1), 29-43 (1984).
64. Bonen A: The expression of lactate transporters (MCT1 and MCT4) in heart and muscle. Eur. J. Appl. Physiol. 86(1), 6-11 (2001).
65. Mccullagh KJ, Poole RC, Halestrap AP, O'Brien M, Bonen A: Role of the lactate transporter (MCT1) in skeletal muscles. Am. J. Physiol. 271(1 Pt 1), E143-E150 (1996).
66. Stanley WC: Myocardial lactate metabolism during exercise. Med. Sci. Sports Exerc. 23(8), 920-924 (1991).
67. Pagliassotti MJ, Donovan CM: Role of cell type in net lactate removal by skeletal muscle. Am. J. Physiol. 258(4 Pt 1), E635-E642 (1990).
68. Sonveaux P, Vegran F, Schroeder T et al.: Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 118(12), 3930-3942 (2008).
69. Broer S, Schneider HP, Broer A, Rahman B, Hamprecht B, Deitmer JW: Characterization of the monocarboxylate transporter 1 expressed in xenopus laevis oocytes by changes in cytosolic pH. Biochem. J. 333 (Pt 1), 167-174 (1998).
70. Dimmer KS, Friedrich B, Lang F, Deitmer JW, Broer S: The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem. J. 350(Pt 1), 219-227 (2000).
71. 2 uptake in human brain during recovery from maximal exercise. J. Physiol. 522(Pt 1), 159-164 (2000).
72. Pellerin L, Magistretti PJ: Neuroenergetics: calling upon astrocytes to satisfy hungry neurons. Neuroscientist 10(1), 53-62 (2004).
73. Pellerin L, Bergersen LH, Halestrap AP, Pierre K: Cellular and subcellular distribution of monocarboxylate transporters in cultured brain cells and in the adult brain. J. Neurosci. Res. 79(1-2), 55-64 (2005).
74. Itoh Y, Esaki T, Shimoji K et al.: Dichloroacetate effects on glucose and lactate oxidation by neurons and astroglia in vitro and on glucose utilization by brain in vivo. Proc. Natl Acad. Sci. USA 100(8), 4879-4884 (2003).
75. Smith D, Pernet A, Hallett WA, Bingham E, Marsden PK, Amiel SA: Lactate: A preferred fuel for human brain metabolism in vivo. J. Cereb. Blood Flow Metab. 23(6), 658-664 (2003).
76. Bouzier AK, Thiaudiere E, Biran M, Rouland R, Canioni P, Merle M: The metabolism of [3-(13)c]lactate in the rat brain is specific of a pyruvate carboxylase-deprived compartment. J. Neurochem. 75(2), 480-486 (2000).
77. Wagner S, Hussain MZ, Hunt TK, Bacic B, Becker HD: Stimulation of fibroblast proliferation by lactate-mediated oxidants. Wound Repair Regen. 12(3), 368-373 (2004).
78. Trabold O, Wagner S, Wicke C et al.: Lactate and oxygen constitute a fundamental regulatory mechanism in wound healing. Wound Repair Regen. 11(6), 504-509 (2003).
79. Wang Q, Morris ME: The role of monocarboxylate transporter 2 and 4 in the transport of γ-hydroxybutyric acid in mammalian cells. Drug Metab. Dispos. 35(8), 1393-1399 (2007).
80. Gladden LB: Muscle as a consumer of lactate. Med. Sci. Sports Exerc. 32(4), 764-771 (2000).
81. Gladden LB: A lactatic perspective on metabolism. Med. Sci. Sports Exerc. 40(3), 477-485 (2008). ■ Provides extensive information on lactate metabolism in many systems.
82. Bourrat-Floeck B, Groebe K, Mueller-Klieser W: Biological response of multicellular EMT6 spheroids to exogenous lactate. Int. J. Cancer 47(5), 792-799 (1991).
83. Katz J, Brand K, Golden S, Rubinstein D: Lactate and pyruvate metabolism and reducing equivalent transfer in Ehrlich ascites tumor. Cancer Res. 34(4), 872-877 (1974).
84. Sauer LA, Dauchy RT: Ketone body, glucose, lactic acid, and amino acid utilization by tumors in vivo in fasted rats. Cancer Res. 43(8), 3497-3503 (1983).
85. Sauer LA, Stayman JW 3rd, Dauchy RT: Amino acid, glucose, and lactic acid utilization in vivo by rat tumors. Cancer Res. 42(10), 4090-4097 (1982).
86. Bouzier AK, Voisin P, Goodwin R, Canioni P, Merle M: Glucose and lactate metabolism in C6 glioma cells: evidence for the preferential utilization of lactate for cell oxidative metabolism. Dev. Neurosci. 20(4-5), 331-338 (1998). ■ This study and [87,88] provide more extensive and detailed research on lactate utilization in tumors as well as information on nuclear magnetic resonance (NMR).
87. Bouzier-Sore AK, Canioni P, Merle M: Effect of exogenous lactate on rat glioma metabolism. J. Neurosci. Res. 65(6), 543-548 (2001). ■ This study and [86,88] provide more extensive and detailed research on lactate utilization in tumors as well as information on NMR.
88. Bouzier AK, Goodwin R, De Gannes FM et al.: Compartmentation of lactate and glucose metabolism in C6 glioma cells. A 13C and 1H NMR study. J. Biol. Chem. 273(42), 27162-27169 (1998). ■ This study and [86,87] provide more extensive and detailed research on lactate utilization in tumors, as well as information on NMR.
89. Chatham JC, Des Rosiers C, Forder JR: Evidence of separate pathways for lactate uptake and release by the perfused rat heart. Am. J. Physiol. 281(4), E794-802 (2001).
90. Izumi H, Torigoe T, Ishiguchi H et al.: Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat. Rev. 29(6), 541-549 (2003).
91. Yamagata M, Hasuda K, Stamato T, Tannock IF: The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. Br. J. Cancer 77(11), 1726-1731 (1998).
92. Helmlinger G, Sckell A, Dellian M, Forbes NS, Jain RK: Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin. Cancer Res. 8(4), 1284-1291 (2002).
93. Swietach P, Vaughan-Jones RD, Harris AL: Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev. 26(2), 299-310 (2007).
94. Wykoff CC, Beasley NJ, Watson PH et al.: Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 60(24), 7075-7083 (2000).
95. 3- anion exchanger binding site to the amino-terminal region of carbonic anhydrase II. Biochemistry 39(44), 13344-13349 (2000).
96. -) anion exchanger AE1. Biochemistry 39(18), 5527-5533 (2000).
97. Alvarez BV, Vilas GL, Casey JR: Metabolon disruption: a mechanism that regulates bicarbonate transport. EMBO J. 24(14), 2499-2511 (2005).
98. Becker HM, Broer S, Deitmer JW: Facilitated lactate transport by MCT1 when coexpressed with the sodium bicarbonate cotransporter (NBC) in xenopus oocytes. Biophys. J. 86(1 Pt 1), 235-247 (2004).
99. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38(2), 285-289 (1997).
100. Moon EJ, Brizel DM, Chi JT, Dewhirst MW: The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antioxid. Redox Signal. 9(8), 1237-1294 (2007). ■ Provides excellent information on hypoxia markers, and is highly relevant to cancer research.
101. Rofstad EK, Sundfor K, Lyng H, Trope CG: Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br. J. Cancer 83(3), 354-359 (2000).
102. Chen JL, Lucas JE, Schroeder T et al.: The genomic analysis of lactic acidosis and acidosis response in human cancers. PLoS Genet. 4(12), E1000293 (2008). ■ One of the first studies we have come across comparing cellular response to hypoxia versus lactosis versus lactic acidosis versus acidosis in both normal and cancer cells.
103. Petrella BL, Lohi J, Brinckerhoff CE: Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 α in von hippel-lindau renal cell carcinoma. Oncogene 24(6), 1043-1052 (2005).
104. Hashimoto T, Masuda S, Taguchi S, Brooks GA: Immunohistochemical analysis of MCT1, MCT2 and MCT4 expression in rat plantaris muscle. J. Physiol. 567(Pt 1), 121-129 (2005).
105. Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN, Halestrap AP: CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J. 19(15), 3896-3904 (2000).
106. Hashimoto T, Hussien R, Brooks GA: Colocalization of MCT1, CD147, and LDH in mitochondrial inner membrane of l6 muscle cells: evidence of a mitochondrial lactate oxidation complex. Am. J. Physiol. 290(6), E1237-1244 (2006).
107. Deora AA, Philp N, Hu J, Bok D, Rodriguez-Boulan E: Mechanisms regulating tissue-specific polarity of monocarboxylate transporters and their chaperone CD147 in kidney and retinal epithelia. Proc. Natl Acad. Sci. USA 102(45), 16245-16250 (2005).
108. Philp NJ, Ochrietor JD, Rudoy C, Muramatsu T, Linser PJ: Loss of MCT1, MCT3, and MCT4 expression in the retinal pigment epithelium and neural retina of the 5A11/basigin-null mouse. Invest. Ophthalmol. Vis. Sci. 44(3), 1305-1311 (2003).
109. Dubouchaud H, Butterfield GE, Wolfel EE, Bergman BC, Brooks GA: Endurance training, expression, and physiology of LDH, MCT1, and MCT4 in human skeletal muscle. Am. J. Physiol. 278(4), E571-E579 (2000).
110. Lin J, Handschin C, Spiegelman BM: Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 1(6), 361-370 (2005).
111. Borthakur A, Saksena S, Gill RK, Alrefai WA, Ramaswamy K, Dudeja PK: Regulation of monocarboxylate transporter 1 (MCT1) promoter by butyrate in human intestinal epithelial cells: involvement of Nf-kB pathway. J. Cell. Biochem. 103(5), 1452-1463 (2008).
112. Enoki T, Yoshida Y, Lally J, Hatta H, Bonen A: Testosterone increases lactate transport, monocarboxylate transporter (MCT) 1 and MCT4 in rat skeletal muscle. J. Physiol. 577(Pt 1), 433-443 (2006).
113. Fanelli A, Grollman EF, Wang D, Philp NJ: MCT1 and its accessory protein CD147 are differentially regulated by TSH in rat thyroid cells. Am. J. Physiol. 285(6), E1223-1229 (2003).
114. Mathupala SP, Parajuli P, Sloan AE: Silencing of monocarboxylate transporters via small interfering ribonucleic acid inhibits glycolysis and induces cell death in malignant glioma: an in vitro study. Neurosurgery 55(6), 1410-1419; discussion 1419 (2004).
115. Ishihara H, Wang H, Drewes LR, Wollheim CB: Overexpression of monocarboxylate transporter and lactate dehydrogenase alters insulin secretory responses to pyruvate and lactate in b cells. J. Clin. Invest. 104(11), 1621-1629 (1999).
116. Maekawa F, Minehira K, Kadomatsu K, Pellerin L: Basal and stimulated lactate fluxes in primary cultures of astrocytes are differentially controlled by distinct proteins. J. Neurochem. 107(3), 789-798 (2008).
117. Cuff MA, Lambert DW, Shirazi-Beechey SP: Substrate-induced regulation of the human colonic monocarboxylate transporter, MCT1. J. Physiol. 539(Pt 2), 361-371 (2002).
118. Clausen MR, Bonnen H, Mortensen PB: Colonic fermentation of dietary fibre to short chain fatty acids in patients with adenomatous polyps and colonic cancer. Gut 32(8), 923-928 (1991).
119. Scheppach W, Bartram HP, Richter F: Role of short-chain fatty acids in the prevention of colorectal cancer. Eur. J. Cancer 31A(7-8), 1077-1080 (1995).
120. Kruh J: Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol. Cell. Biochem. 42(2), 65-82 (1982).
121. Asada K, Miyamoto K, Fukutomi T et al.: Reduced expression of GNA11 and silencing of MCT1 in human breast cancers. Oncology 64(4), 380-388 (2003).
122. Cuff M, Dyer J, Jones M, Shirazi-Beechey S: The human colonic monocarboxylate transporter isoform 1: its potential importance to colonic tissue homeostasis. Gastroenterology 128(3), 676-686 (2005).
123. Lambert DW, Wood IS, Ellis A, Shirazi-Beechey SP: Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy. Br. J. Cancer 86(8), 1262-1269 (2002).
124. Li H, Myeroff L, Smiraglia D et al.: SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc. Natl Acad. Sci. USA 100(14), 8412-8417 (2003).
125. Koukourakis MI, Giatromanolaki A, Bougioukas G, Sivridis E: Lung cancer: a comparative study of metabolism related protein expression in cancer cells and tumor associated stroma. Cancer Biol. Ther. 6(9), 1476-1479 (2007).
126. Chenal J, Pierre K, Pellerin L: Insulin and IGF-1 enhance the expression of the neuronal monocarboxylate transporter MCT2 by translational activation via stimulation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin pathway. Eur. J. Neurosci. 27(1), 53-65 (2008).
127. Chenal J, Pellerin L: Noradrenaline enhances the expression of the neuronal monocarboxylate transporter MCT2 by translational activation via stimulation of PI3K/Akt and the mTOR/S6K pathway. J. Neurochem. 102(2), 389-397 (2007).
128. Ullah MS, Davies AJ, Halestrap AP: The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1α-dependent mechanism. J. Biol. Chem. 281(14), 9030-9037 (2006).
129. Ellis SM, Nabeshima K, Biswas C: Monoclonal antibody preparation and purification of a tumor cell collagenase-stimulatory factor. Cancer Res. 49(12), 3385-3391 (1989).
130. Ishibashi Y, Matsumoto T, Niwa M et al.: CD147 and matrix metalloproteinase-2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma. Cancer 101(9), 1994-2000 (2004).
131. Ueda K, Yamada K, Urashima M et al.: Association of extracellular matrix metalloproteinase inducer in endometrial carcinoma with patient outcomes and clinicopathogenesis using monoclonal antibody 12C3. Oncol. Rep. 17(4), 731-735 (2007).
132. Li Y, Xu J, Chen L et al.: HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection. Histopathology 54(6), 677-687 (2009).
133. Tang Y, Kesavan P, Nakada MT, Yan L: Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (emmprin) expression and matrix metalloproteinase-dependent generation of soluble emmprin. Mol. Cancer Res. 2(2), 73-80 (2004).
134. Yan L, Zucker S, Toole BP: Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb. Haemost. 93(2), 199-204 (2005).
135. Iacono KT, Brown AL, Greene MI, Saouaf SJ: CD147 immunoglobulin superfamily receptor function and role in pathology. Exp. Mol. Pathol. 83(3), 283-295 (2007).
136. Pritchard SC, Nicolson MC, Lloret C et al.: Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy. Oncol. Rep. 8(2), 421-424 (2001).
137. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE: Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J. Pathol. 185(3), 256-261 (1998).
138. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE: Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat. Med. 2(4), 461-462 (1996).
139. Sun J, Hemler ME: Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res. 61(5), 2276-2281 (2001).
140. Kanekura T, Chen X, Kanzaki T: Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int. J. Cancer 99(4), 520-528 (2002).
141. Wu W, Wang R, Liu H et al.: Prediction of prognosis in gallbladder carcinoma by CD147 and MMP-2 immunohistochemistry. Med. Oncol. 26(2), 117-123 (2009).
142. Tang Y, Nakada MT, Rafferty P et al.: Regulation of vascular endothelial growth factor expression by emmprin via the PI3K-AKT signaling pathway. Mol. Cancer Res. 4(6), 371-377 (2006).
143. Jia L, Xu H, Zhao Y, Jiang L, Yu J, Zhang J: Expression of CD147 mediates tumor cells invasion and multidrug resistance in hepatocellular carcinoma. Cancer Invest. 26(10), 977-983 (2008).
144. Reimers N, Zafrakas K, Assmann V et al.: Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin. Cancer Res. 10(10), 3422-3428 (2004).
145. Yang JM, O'Neill P, Jin W et al.: Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to anoikis through inhibition of bim. J. Biol. Chem. 281(14), 9719-9727 (2006).
146. Xu D, Hemler ME: Metabolic activation-related CD147-CD98 complex. Mol. Cell Proteomics 4(8), 1061-1071 (2005).
147. Marieb EA, Zoltan-Jones A, Li R et al.: Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res. 64(4), 1229-1232 (2004).
148. Slomiany MG, Grass GD, Robertson AD et al.: Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res. 69(4), 1293-1301 (2009).
149. Winder WW: Energy-sensing and signaling by AMP-activated protein kinase in skeletal muscle. J. Appl. Physiol. 91(3), 1017-1028 (2001).
150. +-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol. Pharmacol. 70(6), 2108-2115 (2006).
151. Wahl ML, Owen JA, Burd R et al.: Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol. Cancer Ther. 1(8), 617-628 (2002).
152. Mahoney BP, Raghunand N, Baggett B, Gillies RJ: Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem. Pharmacol. 66(7), 1207-1218 (2003).
153. Gallagher SM, Castorino JJ, Philp NJ: Interaction of monocarboxylate transporter 4 with β1-integrin and its role in cell migration. Am. J. Physiol. Cell Physiol. 296(3), C414-C421 (2009).
154. Manning Fox JE, Meredith D, Halestrap AP: Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle. J. Physiol. 529(Pt2), 285-293 (2000).
155. Meredith D, Christian HC: The SLC16 monocaboxylate transporter family. In: Xenobiotica; the fate of foreign compounds in biological systems. Informa Healthcare, London, UK, 38(7-8), 1072-1106 (2008).
156. Jackson VN, Halestrap AP: The kinetics, substrate, and inhibitor specificity of the monocarboxylate (lactate) transporter of rat liver cells determined using the fluorescent intracellular ph indicator, 2́,7́-bis(carboxyethyl)-5(6)-carboxyfluorescein. J. Biol. Chem. 271(2), 861-868 (1996).
157. Carpenter L, Halestrap AP: The kinetics, substrate and inhibitor specificity of the lactate transporter of Ehrlich-Lettre tumour cells studied with the intracellular pH indicator BCECF. Biochem. J. 304 (Pt3), 751-760 (1994).
158. Wilson MC, Jackson VN, Heddle C et al.: Lactic acid efflux from white skeletal muscle is catalyzed by the monocarboxylate transporter isoform MCT3. J. Biol. Chem. 273(26), 15920-15926 (1998).
159. Bueno V, Binet I, Steger U et al.: The specific monocarboxylate transporter (MCT1) inhibitor, ar-c117977, a novel immunosuppressant, prolongs allograft survival in the mouse. Transplantation 84(9), 1204-1207 (2007).
160. Chen X, Lin J, Kanekura T et al.: A small interfering CD147-targeting RNA inhibited the proliferation, invasiveness, and metastatic activity of malignant melanoma. Cancer Res. 66(23), 11323-11330 (2006).
161. Su J, Chen X, Kanekura T: A CD147-targeting siRNA inhibits the proliferation, invasiveness, and VEGF production of human malignant melanoma cells by down-regulating glycolysis. Cancer Lett. 273(1), 140-147 (2009).
162. Zou W, Yang H, Hou X, Zhang W, Chen B, Xin X: Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to paclitaxel in HO-8910pm cells. Cancer Lett. 248(2), 211-218 (2007).
163. Wang L, Wu G, Yu L et al.: Inhibition of CD147 expression reduces tumor cell invasion in human prostate cancer cell line via RNA interference. Cancer Biol. Ther. 5(6), 608-614 (2006).
164. Li QQ, Wang WJ, Xu Jd et al.: Involvement of CD147 in regulation of multidrug resistance to P-gp substrate drugs and in vitro invasion in breast cancer cells. Cancer Sci. 98(7), 1064-1069 (2007).
165. Baba M, Inoue M, Itoh K, Nishizawa Y: Blocking CD147 induces cell death in cancer cells through impairment of glycolytic energy metabolism. Biochem. Biophys. Res. Commun. 374(1), 111-116 (2008).
166. Fishbein WN: Lactate transporter defect: a new disease of muscle. Science 234(4781), 1254-1256 (1986).
167. Le QT, Koong A, Lieskovsky YY et al.: In vivo 1h magnetic resonance spectroscopy of lactate in patients with stage IV head and neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 71(4), 1151-1157 (2008).
168. Li Y, Shang P, Qian AR, Wang L, Yang Y, Chen ZN: Inhibitory effects of antisense RNA of HAB18G/CD147 on invasion of hepatocellular carcinoma cells in vitro. World J. Gastroenterol. 9(10), 2174-2177 (2003).
169. Han ZD, Bi XC, Qin WJ et al.: CD147 expression indicates unfavourable prognosis in prostate cancer. Pathol. Oncol. Res. (2008) (Epub ahead of print).
170. Han ZD, He HC, Bi XC et al.: Expression and clinical significance of CD147 in genitourinary carcinomas. J. Surg. Res. (2008) (Epub ahead of print).
171. Ladanyi M, Antonescu CR, Drobnjak M et al.: The precrystalline cytoplasmic granules of alveolar soft part sarcoma contain monocarboxylate transporter 1 and CD147. Am. J. Pathol. 160(4), 1215-1221 (2002).
172. Kuang YH, Chen X, Su J et al.: Proteome analysis of multidrug resistance of human oral squamous carcinoma cells using CD147 silencing. J. Proteome Res. 7(11), 4784-4791 (2008).
173. Zhang W, Erkan M, Abiatari I et al.: Expression of extracellular matrix metalloproteinase inducer (emmprin/CD147) in pancreatic neoplasm and pancreatic stellate cells. Cancer Biol. Ther. 6(2), 218-227 (2007).
174. Stock C, Schwab A: Protons make tumor cells move like clockwork. Pflugers Arch. 458(5), 981-992 (2009). ■ Stock and Schwab's review on pH regulators is well-done and provides a wealth of information on the influence of pH regulators on cancer.
175. +) exchange, motility, and invasion induced by serum deprivation. J. Biol. Chem. 275(8), 5361-5369 (2000).
176. Stock C, Mueller M, Kraehling H et al.: pH nanoenvironment at the surface of single melanoma cells. Cell Physiol. Biochem. 20(5), 679-686 (2007).
177. 3- cotransport in migration of transformed renal epithelial cells. J. Physiol. 568(Pt 2), 445-458 (2005).
178. Morgan PE, Pastorekova S, Stuart-Tilley AK, Alper SL, Casey JR: Interactions of transmembrane carbonic anhydrase, caix, with bicarbonate transporters. Am. J. Physiol. Cell Physiol. 293(2), C738-748 (2007).